NCT07075718PHASE2, PHASE3Recruiting

Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Glaukos Corporation

Start Date

6/12/2025

Completion Date

3/1/2032

Summary

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Detailed Description

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant Compared to Timolol Ophthalmic Solution 0.5% Administered Twice Daily in Subjects with Open-Angle Glaucoma or Ocular Hypertension

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Diagnosis of open-angle glaucoma or ocular hypertension in the study eye Exclusion Criteria: * Prior incisional glaucoma surgery in the study eye * Prior argon laser trabeculoplasty (ALT) in the study eye * Prior minimally invasive glaucoma (MIGS) surgery in the study eye

Interventions

DRUG

Gen 2 Travoprost Intracameral Implant

DRUG

Timolol eye drops 0.5%

PROCEDURE

Sham Procedure

OTHER

Placebo eye drops

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Glaucoma

Locations

Glaukos Investigative Site

Grand Junction, Colorado 81501

United States

Glaukos Investigative Site

Oklahoma City, Oklahoma 73112

United States

Glaukos Clinical Site

El Paso, Texas 79922

United States